Prospective Evaluation of AI-ECG for SHD Detection
Recruiting
Observational Study
Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)
Pulmonary Hypertension (Diagnosis)
Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis)
Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 590 (estimated)
- Sponsor
- Imperial College London · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to improve the early detection of undiagnosed heart disease, which causes serious health issues, hospital admissions, and high healthcare costs. Researchers are exploring how artificial intelligence (AI) can analyse routine heart tests, called electrocardiograms (ECGs), to detect heart problems. These tests can be done using both traditional ECG machines and portable, wearable devi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged 18-90 years
* No prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD
* Ability to provide informed consent
Exclusion Criteria:
* Severe arrhythmia or unstable cardiovascular disease
* Prior formal diagnosis of HF (including s…
Contacts